PYC Therapeutics (ASX:PYC) Shares Chase Revenue Growth Despite Deep Losses

PYC Therapeutics stock closed at A$2.25 on Friday after a strong run over the past month, yet the fresh numbers still tell a story of a biotech deep in investment mode rather than profit harvest. The headline is the loss from continuing operations of A$43.8 million over the trailing twelve months, set against revenue of A$39.7 million. For long term holders, the bigger question now is how to weigh that loss profile against a P/B of 3.2x, which sits below both direct peers and the broader Australian biotech group.

Is PYC Therapeutics trading at a genuine discount, or simply reflecting the risk of ongoing losses and shareholder dilution? See how the current P/B and fundamentals line up in our valuation analysis for PYC Therapeutics

FY 2026 Earnings Summary

• Revenue, FY 2026 vs. FY 2025 PCP: A$39.68 million vs. A$23.49 million (change reflects higher reported revenue year on year)
• Net Loss, FY 2026 vs. FY 2025 PCP: A$43.34 million loss vs. A$50.30 million loss (change reflects a smaller reported loss year on year)
• Basic EPS, FY 2026 vs. FY 2025 PCP: loss of A$0.059 per share vs. loss of A$0.101 per share (change reflects a smaller loss per share year on year)
• Loss from Continuing Operations, FY 2026 vs. FY 2025 PCP: A$43.77 million loss vs. A$51.01 million loss (change reflects a smaller loss from ongoing operations year on year)

Prefer clean charts to a wall of biotech earnings figures and footnotes? See a full visual look at PYC Therapeutics, including how its valuation compares with its financial track record, in our company report for PYC Therapeutics.

PYC Therapeutics results lean toward cautious optimism

PYC Therapeutics is still loss making, yet the latest year shows the story tilting in a direction that can support a measured bullish view. Revenue of A$39.68 million sits ahead of the prior year’s A$23.49 million, while the reported loss narrowed from A$50.30 million to A$43.34 million and loss per share improved. That lines up with a platform that is spending to advance several RNA programs but gaining some scale. Combined with recent patent wins and an experienced CFO hire, the numbers are at least moving closer to the narrative of a maturing biotech platform.

Loss profile keeps funding and dilution risk in focus

The bear case around PYC Therapeutics still has real footing. The company reported a loss from continuing operations of A$43.77 million and there is no sign yet of self funding from operations. Even with a smaller loss than the prior year, this remains a sizeable cash burn for an early clinical stage biotech and it keeps future funding and potential dilution squarely on the table. Recent share price strength over the past 90 days sits against that backdrop, so any stumble in clinical data or capital markets access could quickly test sentiment.

Compare that internal progress with external expectations, and see whether analysts think PYC Therapeutics is on a credible path or still priced for disappointment with the consensus price target analysis for PYC Therapeutics.

Stay Ahead With PYC Therapeutics

If the mix of ongoing losses and a 3.2x P/B on PYC Therapeutics has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the story develops. Once you decide to take a position, use the Portfolio Command Center to cut through noise and focus on key updates that matter for your holdings. For a broader view, tap into the Community to see how other investors are thinking about the same risks and potential catalysts. This way you can look for hidden strengths or early warning signs sooner and aim to keep a step ahead of the market.

Seeking Alternatives Beyond PYC Therapeutics

Market momentum can shift quickly and fresh ideas often move from quiet to flying before most investors notice. Scan these under the radar opportunities while it matters and get in early.

• Spot sturdy compounders before attention chases them by reviewing hand picked businesses in the list of solid balance sheet and fundamentals stocks (19 results).
• Target early dividend strength while yields remain elevated with a curated group of income stocks in the 8 dividend fortresses.
• Track potential breakout leaders in robotics and automation by focusing on carefully filtered companies inside the 38 robotics and automation stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com